UK markets close in 2 hours 40 minutes
  • FTSE 100

    7,508.71
    +24.36 (+0.33%)
     
  • FTSE 250

    19,814.46
    -35.36 (-0.18%)
     
  • AIM

    951.93
    -3.36 (-0.35%)
     
  • GBP/EUR

    1.1726
    +0.0054 (+0.46%)
     
  • GBP/USD

    1.2499
    -0.0033 (-0.27%)
     
  • BTC-GBP

    23,609.32
    +105.07 (+0.45%)
     
  • CMC Crypto 200

    655.59
    -0.24 (-0.04%)
     
  • S&P 500

    3,941.48
    -32.27 (-0.81%)
     
  • DOW

    31,928.62
    +48.38 (+0.15%)
     
  • CRUDE OIL

    111.08
    +1.31 (+1.19%)
     
  • GOLD FUTURES

    1,854.80
    -10.60 (-0.57%)
     
  • NIKKEI 225

    26,677.80
    -70.34 (-0.26%)
     
  • HANG SENG

    20,171.27
    +59.17 (+0.29%)
     
  • DAX

    13,931.73
    +11.98 (+0.09%)
     
  • CAC 40

    6,258.00
    +4.86 (+0.08%)
     

Nanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer Treatment

  • Oops!
    Something went wrong.
    Please try again later.
·1-min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

By Sam Boughedda

Investing.com — Biotechnology company Nanobiotix (NASDAQ:NBTX) shares rallied 23% on Thursday after it revealed after Wednesday's closing bell that it has enrolled the first patient in a phase 3 study of its treatment for head and neck cancer.

The study is designed to investigate the efficacy and safety of radiotherapy-activated NBTXR3 in high-risk, chemotherapy-ineligible elderly patients with locally advanced head and neck cancer. The trial follows on from the Nanobiotix Study 102, a phase 1 trial evaluating safety and early signs of efficacy.

The U.S. Food and Drug Administration has granted Fast Track designation to investigate radiotherapy-activated NBTXR3, giving it the opportunity for priority review and accelerated approval.

"The first patient enrolled in our global phase III study is a testament to the tireless commitment of our team, investigators, and strategic collaborators," said Laurent Levy, co-founder and chairman of the executive board at Nanobiotix.

Related Articles

Nanobiotix Rallies After Enrolling First Patient in Head and Neck Cancer Treatment

S&P 500 Slips as Tech Remains Pain Trade Ahead of Jobs Data

S&P 500 ends jumpy session nearly flat, a day after sell-off

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting